Metagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate Outlook

New name reflects the Company’s strategic evolution focused on later-stage preclinical assets leveraging its most advanced, signature ...
Le Lézard

AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors

AbbVie and RemeGen today announced an exclusive licensing agreement for the development, manufacturing and commercialization ...

Metagenomi, Inc.: Metagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate Outlook

New name reflects the Company's strategic evolution focused on later-stage preclinical assets leveraging its most advanced, signature gene-editing capabilities Pre-IND meeting held in 4Q 2025 followin ...

CRITICAL METALS CORP NASDAQ-CRML Acquires an Integrated Rare Earth Element Assay Analysis Lab Facility to Support Faster Drilling Assay Results for 2026 Drilling …

Critical Metals Corp has approved and ordered a turnkey Integrated Mobile Geochemical Analysis Centre from Bromet to support ...

Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference

Full-year 2025 preliminary1 U.S. net product revenues of $689 millionSYFOVRE® (pegcetacoplan injection) total injection demand grew 17% year-over-year; regulatory submission for prefilled syringe ...